Eli Lilly (LLY)
(Delayed Data from NYSE)
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
Zacks News
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
by Zacks Equity Research
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
by Zacks Equity Research
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
by Zacks Equity Research
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWB
Stocks to Buy and Hold for 5 Years
by Tracey Ryniec
What if you fell asleep and woke up 5 years later? Would you feel confident in your stock portfolio?
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
by Zacks Equity Research
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $909.32, moving -1.65% from the previous trading session.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QUS
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
by Zacks Equity Research
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
by Zacks Equity Research
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
by Kinjel Shah
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
by Zacks Equity Research
The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
by Zacks Equity Research
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
by Kinjel Shah
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.